BACKGROUND: Tyrosine kinase inhibitors are standard treatment in patients with metastatic renal cell carcinoma (mRCC). Several studies have indicated that side-effects including hypothyroidism may serve as potential predictive biomarkers of treatment efficacy. PATIENTS AND METHODS: All patients with clear cell mRCC treated with sunitinib in the first-line setting in our Center between November 2008 and October 2013 were included. Thyroid function was assessed after every 2 cycles. Prognostic factors were tested using Cox proportional hazards model for univariate analysis. RESULTS: During treatment, 29.3% developed hypothyroidism, with a median of peak TSH values of 34.4 mIU/L. Patients who had both TSH >4 mIU/L and were receiving substitution therapy with levothyroxine had prolonged PFS compared to all other patients (25.3 months vs. 9.0 months; p=0.042). CONCLUSION: The rate of hypothyroidism as a side-effect of sunitinib in patients with mRCC is significant. Patients with symptomatic hypothyroidism experienced significantly longer PFS, but without difference in OS. Copyright
BACKGROUND: Tyrosine kinase inhibitors are standard treatment in patients with metastatic renal cell carcinoma (mRCC). Several studies have indicated that side-effects including hypothyroidism may serve as potential predictive biomarkers of treatment efficacy. PATIENTS AND METHODS: All patients with clear cell mRCC treated with sunitinib in the first-line setting in our Center between November 2008 and October 2013 were included. Thyroid function was assessed after every 2 cycles. Prognostic factors were tested using Cox proportional hazards model for univariate analysis. RESULTS: During treatment, 29.3% developed hypothyroidism, with a median of peak TSH values of 34.4 mIU/L. Patients who had both TSH >4 mIU/L and were receiving substitution therapy with levothyroxine had prolonged PFS compared to all other patients (25.3 months vs. 9.0 months; p=0.042). CONCLUSION: The rate of hypothyroidism as a side-effect of sunitinib in patients with mRCC is significant. Patients with symptomatic hypothyroidism experienced significantly longer PFS, but without difference in OS. Copyright
Authors: Camillo Porta; Martin E Gore; Brian I Rini; Bernard Escudier; Subramanian Hariharan; Lorna P Charles; Liqiang Yang; Liza DeAnnuntis; Robert J Motzer Journal: Eur Urol Date: 2015-07-26 Impact factor: 20.096
Authors: Anna Buda-Nowak; Jakub Kucharz; Paulina Dumnicka; Marek Kuzniewski; Roman Maria Herman; Aneta L Zygulska; Beata Kusnierz-Cabala Journal: Med Oncol Date: 2017-03-25 Impact factor: 3.064
Authors: Martin Pilskog; Leif Bostad; Reidunn J Edelmann; Lars A Akslen; Christian Beisland; Oddbjørn Straume Journal: J Pathol Clin Res Date: 2018-03-05
Authors: Maria T Bourlon; Dexiang Gao; Sara Trigero; Julia E Clemons; Kathryn Breaker; Elaine T Lam; Thomas W Flaig Journal: Cancer Med Date: 2016-10-19 Impact factor: 4.452